Walter Blättler

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Proterris (Portugal) - Investigação e Desenvolvimento de Produtos Farmacêuticos, Sociedade Unipessoal Lda. develops Carbon Monoxide-Releasing Molecules (CORMs) for therepy. The company was founded by Carlos José Rodrigues Crispim Romão, Werner Ernest Hass, Nuno Manuel de Castro Santos Arante e Oliveira and Stan Kugell on January 4, 2002 and is headquartered in Oeiras, Portugal.

CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA.

Formation Biologics Corp. operates as a biopharmaceutical drug development company. It discovers and develops drugs and medicines for treatment of patients with cancers and orphan diseases. The company was founded in 2011 and is headquartered in Austin, TX.

35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov.

Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada.

Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA.